Maturation inhibitor
Thematuration inhibitorsare a class of antiviral drugs for the treatment of infection withHIV.They act by interfering with the maturation of the virus. Specifically, drugs in this class disrupt the final step in the processing of the HIV-1gagprotein,the cleavage of its immediate precursor by the enzymeHIV-1 protease.Unlike the class of drugs known asprotease inhibitors,maturation inhibitors bind thegagprotein, not the protease. This leads to the formation of noninfectious, immature virus particles, incapable of infecting other cells. No other class of drugs shares this mechanism of action, thus maturation inhibitors retain inhibitory activity against HIV infections with resistance.[1][2][3][4]
There are no currently available drugs from the class; however several clinical trials have been conducted. The first maturation inhibitor to be studied in humans wasbevirimat,[5]another was MPC-9055 (vivecon).[6]Both were developed byMyriad Genetics,which has discontinued the maturation inhibitor program in 2010.[7]Others in development include BMS-2838232.
References
[edit]- ^Salzwedel K, Martin DE, Sakalian M (2007)."Maturation inhibitors: a new therapeutic class targets the virus structure".AIDS Rev.9(3): 162–72.PMID17982941.Archived fromthe originalon 2016-08-03.Retrieved2009-02-21.
- ^Adamson CS, Salzwedel K, Freed EO (August 2009)."Virus maturation as a new HIV-1 therapeutic target".Expert Opin. Ther. Targets.13(8): 895–908.doi:10.1517/14728220903039714.PMC2737327.PMID19534569.
- ^Waheed AA, Freed EO (January 2012)."HIV type 1gagas a target for antiviral therapy ".AIDS Res. Hum. Retroviruses.28(1): 54–75.doi:10.1089/AID.2011.0230.PMC3251841.PMID21848364.
- ^Jiang Y, Liu X, de Clercq E (2011). "New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle".Curr. Med. Chem.18(1): 16–28.doi:10.2174/092986711793979751.PMID21110817.
- ^Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE (2007)."Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice".PLOS ONE.2(11): e1251.Bibcode:2007PLoSO...2.1251S.doi:10.1371/journal.pone.0001251.PMC2080775.PMID18043758.
- ^"New HIV maturation inhibitor MPC-9055".National AIDS Treatment Advocacy Project. 17 September 2008.Retrieved10 June2012.
- ^"Myriad Genetics suspends its HIV Maturation Inhibitor Program".AIDSmeds. 8 June 2012. Archived fromthe originalon 8 September 2015.Retrieved27 June2012.
 | Thisantiinfectivedrugarticle is astub.You can help Wikipedia byexpanding it. |